PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

NCT07209059 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

NETWORK

Sponsor class

Conditions

Hodgkin Lymphoma
Hodgkin Disease
Advanced Hodgkin Lymphoma

Interventions

DRUG: Nivolumab
OTHER: N-EACOPD-14
OTHER: N-AVD

Sponsor

National Research Center for Hematology, Russia